Search

Your search keyword '"Brockow K"' showing total 548 results
Start Over Author "Brockow K" Publication Type Academic Journals
548 results on '"Brockow K"'

1. Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus

Author

Ingen-Housz-Oro, S, Schmidt, V, Ameri, MM, Abe, R, Brassard, A, Mostaghimi, A, Paller, AS, Romano, A, Didona, B, Kaffenberger, BH, Ben Said, B, Thong, BYH, Ramsay, B, Brezinova, E, Milpied, B, Mortz, CG, Chu, CY, Sotozono, C, Gueudry, J, Fortune, DG, Dridi, SM, Tartar, D, Do-Pham, G, Gabison, E, Phillips, EJ, Lewis, F, Salavastru, C, Horvath, B, Dart, J, Setterfield, J, Newman, J, Schulz, JT, Delcampe, A, Brockow, K, Seminario-Vidal, L, Jörg, L, Watson, MP, Gonçalo, M, Lucas, M, Torres, M, Noe, MH, Hama, N, Shear, NH, O’Reilly, P, Wolkenstein, P, Romanelli, P, Dodiuk-Gad, RP, Micheletti, RG, Tiplica, GS, Sheridan, R, Rauz, S, Ahmad, S, Chua, SL, Flynn, TH, Pichler, W, Le, ST, Maverakis, E, Walsh, S, French, LE, and Brüggen, MC

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Dental/Oral and Craniofacial Disease, Humans, Stevens-Johnson Syndrome, Consensus, Skin, Disease Progression, Epidermal necrolysis, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Sequelae, Quality of life, Delphi, Other Medical and Health Sciences, Genetics & Heredity, Genetics, Clinical sciences
Abstract

BackgroundLong-term sequelae are frequent and often disabling after epidermal necrolysis (Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)). However, consensus on the modalities of management of these sequelae is lacking.ObjectivesWe conducted an international multicentric DELPHI exercise to establish a multidisciplinary expert consensus to standardize recommendations regarding management of SJS/TEN sequelae.MethodsParticipants were sent a survey via the online tool "Survey Monkey" consisting of 54 statements organized into 8 topics: general recommendations, professionals involved, skin, oral mucosa and teeth, eyes, genital area, mental health, and allergy workup. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). Results were analyzed according to the RAND/UCLA Appropriateness Method.ResultsFifty-two healthcare professionals participated. After the first round, a consensus was obtained for 100% of 54 initially proposed statements (disagreement index

Published
2023

2. Flow‐based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper.

Author

Mayorga, C., Çelik, G. E., Pascal, M., Hoffmann, H. J., Eberlein, B., Torres, M. J., Brockow, K., Garvey, L. H., Barbaud, A., Madrigal‐Burgaleta, R., Caubet, J. C., and Ebo, D. G.

Subjects
DRUG allergy, ALLERGIES, TASK forces, NEUROMUSCULAR blocking agents, BASOPHILS
Abstract

Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) "Basophil activation test in the evaluation of Drug Hypersensitivity Reactions" from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus‐based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug‐specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti‐inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Increasing the COVID‐19 immunization rate through allergy testing.

Author

Bent, R. K., Weinbrenner, J., Faihs, V., Steffens, S., Nau, T., Vitus, M., Mathes, S., Darsow, U., Biedermann, T., and Brockow, K.

Subjects
COVID-19 pandemic, IMMUNIZATION, ALLERGIES, LIKERT scale, COVID-19 vaccines, ITCHING
Abstract

Background: Vaccination of the population is required to combat the COVID‐19 pandemic. Allergy testing could reduce anxiety towards COVID‐19 vaccination and thereby may increase vaccination rate, however, its effectiveness remains unclear. Methods: One hundred and thirty prospective real‐life patients in need of but not daring to get vaccinated asked for allergy workup for COVID‐19 vaccine hypersensitivity in 2021/2022. Characterization of patients, identification of anxieties, decrease of patient's anxiety levels, overall vaccination rate and adverse reactions after vaccination were assessed. Results: Tested patients were characterized by being female (91.5%) and having a high rate of previous allergies (e.g. to food 55.4%, drugs 54.6%, or previous vaccinations 50%) and dermatological disease (29.2%) but not always had medical contraindications for COVID‐19 vaccination. Sixty one patients (49.6%) were highly concerned (4‐6, Likert scale 0‐6) about vaccination and 47 (37.6%) expressed resolving thoughts about vaccinaion anaphylaxis (3‐6, Likert scale 0‐6). However only 35 patients (28.5%) were scared of getting COVID‐19 within 2 months (4–6, Likert scale 0–6) and only 11 (9%) patients had high expectations of getting COVID‐19 (4–6, Likert scale 0–6). Allergy testing significantly (p < 0.01 to p < 0.05 respectively) reduced the median anxiety of allergic symptoms following vaccination: dyspnoea (4.2–3.1), to faint (3.7–2.7), long‐term consequences (3.6–2.2), pruritus (3.4–2.6), skin rash (3.3–2.6) and death (3.2–2.6). After allergy testing, most patients (108/122, 88.5%) let themselves be vaccinated within 60 days. Revaccinated patients with previous symptoms experienced a reduction of symptoms (p < 0.05) upon revaccination. Conclusions: Patients not daring to get vaccinated have more anxiety towards vaccination than to acquire COVID‐19. For those, allergy testing excludes vaccine allergy, and is a tool to increase vaccination willingness and thereby helps to combat vaccination hesitancy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Validation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of KIT D816V mutation analysis.

Author

Gebhard, J., Horny, H.‐P., Kristensen, T., Broesby‐Olsen, S., Zink, A., Biedermann, T., and Brockow, K.

Subjects
MAST cell disease, URTICARIA, SURGICAL margin, ATOPIC dermatitis, MAST cells, CD30 antigen, SENSITIVITY & specificity (Statistics)
Abstract

Background: Cutaneous lesions of mastocytosis (CLM) are often subtle and may require biopsy. However, dermatohistopathological criteria for CLM remain undefined. Objectives: To establish criteria for CLM by validating histological and molecular parameters. Methods: In skin samples from Caucasian patients with CLM and controls (atopic dermatitis, chronic urticaria, pruritus, tissue from tumor safety margin excisions), mast cell (MC) numbers, size, shape, distribution, immunostainability with a large panel of markers, pigmentation and presence of KIT D816V mutation were analysed. Results: Forty‐seven CLM patients (32 maculopapular cutaneous mastocytosis (MPCM), 15 mastocytomas) and 36 controls were included. Mastocytomas were easily identified by densely packed cuboidal MCs. In MPCM, skin MC density in CD117 stains was higher in CLM patients than in controls (P < 0.0001) and values correlated closely (r = 0.65, P < 0.0001) to results in tryptase stains. The optimized upper dermis cut‐off number of 62 MC/mm2 had a sensitivity and specificity of 92% in both stainings, corresponding to approximately 12 MC/high power field (HPF). MC size was larger in MPCM than in controls (P = 0.01). Interstitial (= not perivascular or periadnexal) MCs and stronger basal pigmentation of the epidermis were indicative of MPCM (P < 0.0001 each) and clusters of >3 nucleated MC/HPF exclusively found in MCPM. Surface markers CD2, CD25 and CD30 stained T‐lymphocytes, but only negligibly CLM MC. The KIT D816V mutation in formalin fixed paraffin embedded (FFPE) skin was evaluable in 87.5% of MCPM patients and had both 100% sensitivity and specificity. Conclusions: MPCM can be predicted by major and minor criteria combined in a scoring model. Presence of D816V mutation in FFPE skin and MC density > 27/HPF are >95%‐specific major criteria for MPCM. MC densities 12/HPF, interstitial MC, clusters and basal pigmentation are minor criteria. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis

Author

Valent, P., Escribano, L., Broesby-Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N. G., Kristensen, T., Butterfield, J. H., Triggiani, M., Alvarez-Twose, I., Reiter, A., Sperr, W. R., Sotlar, K., Yavuz, S., Kluin-Nelemans, H. C., Hermine, O., Radia, D., van Doormaal, J. J., Gotlib, J., Orfao, A., Siebenhaar, F., Schwartz, L. B., Castells, M., Maurer, M., Horny, H.-P., Akin, C., Metcalfe, D. D., and Arock, M.

Published
2014
Full Text
View/download PDF

27. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology

Author

Muraro, A., Roberts, G., Worm, M., Bilò, M. B., Brockow, K., Rivas, Fernández M., Santos, A. F., Zolkipli, Z. Q., Bellou, A., Beyer, K., Bindslev-Jensen, C., Cardona, V., Clark, A. T., Demoly, P., Dubois, A. E. J., DunnGalvin, A., Eigenmann, P., Halken, S., Harada, L., Lack, G., Jutel, M., Niggemann, B., Ruëff, F., Timmermans, F., Vlieg–Boerstra, B. J., Werfel, T., Dhami, S., Panesar, S., Akdis, C. A., and Sheikh, A.

Published
2014
Full Text
View/download PDF

28. Global Allergy Forum and Second Davos Declaration 2013 Allergy: Barriers to cure – challenges and actions to be taken

Author

Ring, J., Akdis, C., Lauener, R., Schäppi, G., Traidl-Hoffmann, C., Akdis, M., Ammann, W., Behrendt, H., Bieber, T., Biedermann, T., Bienenstock, J., Blaser, K., Braun-Fahrländer, C., Brockow, K., Buters, J., Crameri, R., Darsow, U., Denburg, J. A., Eyerich, K., Frei, R., Galli, S. J., Gutermuth, J., Holt, P., Koren, H., Leung, D., Müller, U., Muraro, A., Ollert, M., OʼMahony, L., Pawankar, R., Platts-Mills, T., Rhyner, C., Rosenwasser, L. J., Schmid-Grendelmeier, P., Schmidt-Weber, C. B., Schmutz, W., Simon, D., Simon, H. U., Sofiev, M., van Hage, M., and van Ree, R.

Published
2014
Full Text
View/download PDF

32. International Consensus on drug allergy

Author

Demoly, P., Adkinson, N. F., Brockow, K., Castells, M., Chiriac, A. M., Greenberger, P. A., Khan, D. A., Lang, D. M., Park, H.-S., Pichler, W., Sanchez-Borges, M., Shiohara, T., and Thong, B. Y.-H.

Published
2014
Full Text
View/download PDF

36. Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Allergy Interest Group position paper

Author

Brockow, K., Garvey, L. H., Aberer, W., Atanaskovic-Markovic, M., Barbaud, A., Bilo, M. B., Bircher, A., Blanca, M., Bonadonna, B., Campi, P., Castro, E., Cernadas, J. R., Chiriac, A. M., Demoly, P., Grosber, M., Gooi, J., Lombardo, C., Mertes, P. M., Mosbech, H., Nasser, S., Pagani, M., Ring, J., Romano, A., Scherer, K., Schnyder, B., Testi, S., Torres, M., Trautmann, A., and Terreehorst, I.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results